Chuangyuan Chuangyuan Biotechnology has been developing adjoint diagnosis for many years. This year, we will continue to cooperate with pharmaceutical companies and clinicians to carry out concomitant diagnosis for 10 autoimmune diseases, hoping to build the first high-throughput sequencing platform for autoimmune diseases-related genes in Taiwan Province Province and step into the next milestone in the era of precision medicine.
Cai Zhengxian, CEO of Chuangyuan Biotechnology, pointed out that medical literature has confirmed that autoimmune diseases are directly related to gene mutation. Therefore, in the clinical trials of CAPS drugs in the United States, suitable patients were screened out through genetic testing, and 97% of the subjects' symptoms were obviously relieved, which made the blind results statistically significant in clinic, which also highlighted the importance of genetic testing in selecting clinical drugs related to genes.
What is adjoint diagnosis? The characteristics of the matching diagnostic instrument are: 1. It can identify patients who are most likely to benefit from a particular drug. 2. It can determine the risk that patients may increase side effects due to the use of specific drugs. 3. Can monitor the reaction of adjusting treatment methods (such as course of treatment, dosage, interruption of treatment, etc.). ) to achieve the purpose of improving safety or effectiveness. Simply put, it is to give the right medicine and dosage to the right patient through accompanying diagnosis, so as to achieve the purpose of precise medical treatment.
The new CAPS drugs are covered by medical insurance, and a multi-gene sequencing platform will be established in the future. Due to the clear genetic test of drug applicability and the experience of patients' family members in improving their own inflammatory and other fatal symptoms after using the drug, Novartis finally got health insurance coverage last year and became a new drug for CAPS. Cai Zhengxian also mentioned that Chuangyuan will cooperate with Novartis and clinicians who have accumulated experience for a long time to expand the genetic testing of other autoimmune diseases except CAPS. It is expected that within three years, the first multi-gene sequencing platform related to autoimmune diseases will be established in Taiwan Province Province by using the rapid gene sequencing method in Qualcomm.
In addition to providing clinically suspected patients with various tests related to their own inflammatory genes and finding suitable drugs as soon as possible, on the other hand, it can also help doctors to find patients at risk of such diseases as soon as possible, carry out testing and preventive measures, reduce the burden on subsequent patients and families, reduce social medical costs, and truly realize the contribution of personalized medicine in precision medical care.
Subject: CAPS, adjoint diagnosis, genetics, gene detection, gene technology, new knowledge of biomedicine, precision medicine, Novartis.